Parse Biosciences Launches Whole Transcriptome
Kit to Dramatically Scale Single Cell Sequencing
Now commercially available, the Whole Transcriptome Kit enables researchers in neuroscience, immunology, oncology, as well as other areas of scientific study, to achieve industry-leading detail on cell types and subtypes
Seattle, WA, February 18, 2021
Parse Biosciences., a company providing researchers with scalable and flexible single cell sequencing solutions, today announced the launch of their Single Cell Whole Transcriptome Kit. The kit, which was previously available only through Parse’s early access program, is now generally available to all researchers in North America.
The Whole Transcriptome Kit from Parse Biosciences contains everything needed to run a single cell experiment with 100,000 cells across 48 samples. Previously, single cell sequencing solutions demanded that researchers invest in expensive lab equipment to get started. Now, with the launch of Parse Bioscience’s Whole Transcriptome Kit, researchers have a reliable and scalable, end-to-end single cell sequencing technology that utilizes only basic lab equipment.
“For too long, labs have been held back by technologies that not only compromise on data quality, but which also don’t scale to match researchers’ ambitions,” said Alex Rosenberg, co-founder and CEO of Parse. “Through our Whole Transcriptome Kit, we support researchers who are taking on some of the most challenging problems in biology — spanning neuroscience, immunology, and beyond. We provide them with a technology that is more scalable and offers higher resolution than anything else on the market, including droplet-based solutions.”
Since their pioneering paper on SPLiT-seq published in Science in 2018, Parse Biosciences has continued to refine their technology. The Whole Transcriptome Kit marks a tremendous improvement from the proof-of-concept introduced in the company’s paper, with improved sensitivity and industry-leading data resolution.
Key features of the Single Cell Whole Transcriptome Kit include:
Accommodation of up to 48 unique biological samples and up to 100,000 cells or nuclei with a single kit.
Separation of the sample extraction from downstream library preparation steps empowers researchers to run fixed samples collected on different dates together in a single experiment.
Long-term storage (up to 6 months) of fixed samples — with no impact on gene expression or the number of transcripts detected per cell.
Full compatibility with both cells and nuclei gives researchers the choice on how to prepare their samples
A lower doublet rate than anything else on the market. Researchers can trust the data is true single cell data.
Increased sensitivity enables high transcript detection including cells with low RNA content such as PBMCs.
No custom instrument means researchers can get started quickly with no capital costs. Through split-pool combinatorial barcoding, researchers can bypass the need for expensive and complicated microfluidic instruments.
The Parse Biosciences pipeline is an out-of-the-box software tool that you can run locally to go straight from sequencing files to processed data. The pipeline produces interactive outputs that make it possible to browse gene expression across different biological samples and cell populations.
Through their early access program, Parse Biosciences’ Whole Transcriptome Kit has already been used in 50 labs across the country, providing researchers with improved resolution and throughput in their experiments.
“Combinatorial barcoding is going to transform the way people do single cell sequencing. It’s simple, elegant, and incredibly scalable,” said Lawrence T. Reiter, PhD and Professor of Neurology at The University of Tennessee Health Science Center. “With Parse Biosciences’ Whole Transcriptome Kit, I’ve been able to finally reveal the neuronal and glial characteristics of our dental pulp stem cell neuron cultures.”
With the launch of the Whole Transcriptome Kit, Parse Biosciences is also making available three datasets encompassing cell lines, brain nuclei, and immune cells. Through these datasets, researchers can see firsthand how the Whole Transcriptome Kit enables highly sensitive gene detection across a wide variety of sample types.
“With these datasets, our goal is to give researchers the ability to explore the capabilities of this technology before they ever bring it into their own labs,” said Charlie Roco, co-founder and CTO of Parse Biosciences. “This is really a whole new level of data, and we want to open it up and use it to inspire researchers. Our goal is that as researchers begin to manipulate our datasets, they realize the extent that single cell sequencing can support them in their research.”
Split Biosciences, now Parse Biosciences, Announces $7M in Series A Funding to Democratize Single-Cell RNA Sequencing
As adoption of scRNA-seq in industry and academia accelerates, Parse Biosciences (formerly Split Bio) offers the most flexible and scalable single cell sequencing kit, no custom instrument needed
Seattle, WA, January 26, 2021
Split Biosciences, a company providing researchers scalable and flexible single cell sequencing solutions, today announced $7M in Series A funding. The funding round was led by Bioeconomy Capital, an early stage VC firm specializing in companies developing life science tools, with participation from new and existing angel investors. Split Bio also announced a rebrand of the company to Parse Biosciences.
The new funding will be used to continue scaling the commercial roll-out of Parse Bioscience’s Whole Transcriptome Kit, which enables researchers to profile up to 100,000 cells in parallel across up to 48 samples. In addition to increased scalability, Parse Biosciences’s technology also provides researchers with higher data quality. Parse enables researchers to increase gene detection in individual cells, while dramatically reducing confounding artifacts that are common in single cell sequencing experiments.
The new brand comes as Parse Biosciences matures beyond the initial academic research upon which the company was founded and in the wake of significant advancements in their technology.
“We have spent the last three years developing a product that more scientists could actually use,” said Charlie Roco, co-founder and CTO of Parse Biosciences. “Our kits are now operating at a higher level than anything else we’ve seen on the market and our company has evolved beyond our original SPLiT-seq method. We wanted our brand to reflect that.”
Researchers in both the pharmaceutical industry and academia have increasingly leveraged single cell technologies to drive discovery. Single cell RNA sequencing continues to transform research across every field of biology and medicine, and the pace of adoption shows no sign of slowing down, with the global single-cell analysis market expected to continue growing at a CAGR of 18% through 2027.
Through single cell sequencing, researchers are able to interrogate biological systems through a new lens, leading to insights that were previously obscured without single cell resolution. To date, however, researchers are limited in their options. While other single cell sequencing solutions on the market require expensive lab equipment, Parse Biosciences has developed a technique that enables single cell sequencing with only basic lab equipment. By removing the most prohibitive barrier to access, the company’s kits help bring single cell sequencing to virtually every research lab around the world.
“From the sheer scalability of their technology, to the entirely unique flexibility that their single cell sequencing kits provides to researchers, Parse Biosciences is creating a new standard for the single cell market,” said Rob Carlson, managing director at Bioeconomy Capital. “We’re excited to back this emerging leader of the industry and support their continued expansion to serve labs all over the world.”
Parse Biosciences enables researchers to scale their single-cell sequencing and achieve more flexible workflows. By using combinatorial cDNA barcoding within cells themselves, Parse Biosciences’s technology allows researchers to eliminate the need for complex and expensive microfluidic instruments. Additionally, the company’s technology enables samples to be fixed, frozen and stored, allowing researchers to separate out the sample extraction from downstream library preparation steps. This capability empowers researchers to run fixed samples collected on different dates together in a single experiment, providing greater control over sample handling and reducing handling errors.
Parse Biosciences’ Whole Transcriptome Kit is already used in 40 labs across the country, providing these researchers with improved resolution and throughput in their experiments. The company also supplies a computational pipeline which generates an experimental report along with a gene-cell count matrix and other processed data that integrates into existing open source tools, such as Seurat and Scanpy.
“At Parse Biosciences, we believe broad and widespread access to tools to understand biology is critical to solving the most pressing health challenges of our generation, from eradicating infectious diseases, to developing successful targeted therapies,” said Alex Rosenberg, CEO and co-founder of Parse Biosciences. “We know that, as a technology, single cell sequencing holds the key to accelerating progress in human health and scientific research. We’re excited to have Bioeconomy Capital’s support as we continue to scale our offerings to researchers and provide labs with an effective and flexible new technology to support their critical work.”
Split Bio Brings Total Financing to Over $2M
Seattle, WA | August 30th, 2019
Split Bio announced the closing of a bridge financing round, bringing the company’s total funding to over $2M. Split Bio will use these funds to scale-up manufacturing of their Whole Transcriptome Single Cell RNA-sequencing kits. These funds will also support ongoing research and development for follow-on applications.
Split Bio offers the most scalable single cell RNA-sequencing solution, enabling researchers to process up to 100,000 cells across 48 unique samples in parallel. Split Bio’s solution gives users flexibility in their experimental design by allowing them to fix and store cells after sample extraction rather than requiring users to proceed directly to single cell barcoding. This makes it possible to collect biological samples across different days but process all the samples together using a single kit. These standalone kits can be used in any molecular biology lab without the need for custom instruments.
Split Bio is expanding and seeking highly innovative individuals looking to make a large scale impact on the research community. The Seattle based team is currently hiring Research Associates, Scientists, and Computational Biologists. For more information visit the Careers page.
Split Biosciences Awarded Small Business Innovation Research (SBIR) Grant from the National Science Foundation
Small Business Innovation Research Program Provides Seed Funding for R&D
Seattle, WA | July 2, 2019
Split Biosciences has been awarded a National Science Foundation (NSF) Small Business Innovation Research (SBIR) grant for $225,000 to further research and development (R&D) work towards democratizing single-cell RNA sequencing.
The Seattle-based company is developing a family of kits that enable researchers to perform scalable single-cell sequencing experiments. Unlike existing single cell technologies, Split Bio’s kits use only standard molecular biology equipment and do not require the upfront purchase of a custom instrument. The company’s innovative approach to single-cell sequencing is based upon a combinatorial barcoding strategy published in Science in 2018.
The one-year grant will pay for continued development on the company’s single-cell RNA-sequencing kit. The kit will enable researchers to sequence up to 100,000 cells across 48 different samples in a single experiment. Researchers interested in participating in an Early Access Program can find more information at splitbio.com.
About the National Science Foundation's Small Business Programs: America’s Seed Fund powered by NSF awards $200 million annually to startups and small businesses, transforming scientific discovery into products and services with commercial and societal impact. Startups working across almost all areas of science and technology can receive up to $1.5 million in non-dilutive funds to support research and development (R&D), helping de-risk technology for commercial success. America’s Seed Fund is congressionally mandated through the SBIR program. The NSF is an independent federal agency with a budget of about $8.1 billion that supports fundamental research and education across all fields of science and engineering.
Completion of Seed Financing
Seattle, WA | October 12, 2018
Split Biosciences, a Seattle based single-cell analysis company, today announced the recent completion of its seed financing.
Split Biosciences is a University of Washington spinout and will use the financing to build upon the groundbreaking single-cell RNA-sequencing technology--SPLiT-seq--published in Science in early 2018. The technology addresses current limitations of single-cell RNA-sequencing through the use of multiple rounds of in-situ combinatorial barcoding.